BioSpace News Archive

AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection, today announced the initiation of patient dosing in a Phase 2 study of ABP-450 for the treatment of cervical dystonia.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new preclinical research demonstrating the ability of VIR-7831, the company’s investigational SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) monoclonal antibody (mAb), to maintain its neutralizing activity against a mutation in the receptor binding domain (RBD) of SARS-CoV-2, called L452R,

GUNNAR Embarks on Year Long Fundraising Activations to Support Research and Treatment of Childhood Cancer and Other Life-Threatening Diseases

IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that destroys tumors by freezing, announced today that it has been granted Designation as a Breakthrough Device from the U.S. Food and Drug Administration (FDA) for its lead asset, ProSense®, and proposed indication for use

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the 20th Annual Needham Virtual Healthcare Conference.

Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, April 12, 2021 to review new data for multiple research- and clinical-stage programs across its precision oncology and hematology portfolio.

CRH Medical Corporation announces that it has completed an accretive transaction whereby the Company has acquired the remaining 25% interest in Lake Lanier Anesthesia Associates a gastroenterology anesthesia practice located in Georgia.

Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company’s method for inhibiting formation of biofilms.

n-Lorem Foundation, a nonprofit organization that provides free, lifetime supplies of individualized RNA-targeted medicines to patients living with ultra-rare diseases, today announced a new partnership with Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases.

Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance.